IPNews® – The Federal Circuit on Friday affirmed a Texas federal court’s patent infringement finding and accompanying injunction barring three generic drug manufacturers from making, selling or marketing generic versions of Pozen Inc.’s migraine treatment Treximet.
Par Pharmaceutical Inc., Alphapharm Pty Ltd. and Dr. Reddy’s Laboratories Inc. could not overcome the presumption of validity of